Known targets — ChEMBL curated mechanism
ABCC8ACEADORA1ADORA2AADORA2BADORA3ALDH5A1ALOX5ALOX5APATP4AATP4BBRAFCA1CA12CA2CA4CYSLTR1DHFRDPEP1EDNRAEDNRBESR2F10FDPSFGF1GABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGARTGNRHRGSC1HMGCRIMPDH1IMPDH2KCNJ11LY96NOD2NR3C1NS3NS4ANS5bP2RY1P2RY12P2RY2P2RY4P2RY6PBP2XPDE3APDE3BPDE4APDE4BPDE4CPDE4DPDK1PDK2PDK3PDK4PPARGPPATPTGIRPTGS1PTGS2RAF1RYR1RYR3SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASERPINC1SLC12A1SLC12A3SYKTHRATHRBTLR3TLR4TLR9TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYMSVKORC1XDHblablaIMP-1blaOXA-33blaOXA-58blaT-3blaT-4blaT-5blaT-6dacAdacBdacCfolAfolPfolP1ftsIfusAgaggyrAgyrBmecAmrcAmrcBmrdApbp1apbp1bpbp2pbp2apbp2bpbp3pbp4pbpApbpBpbpCpbpFpolponBrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpoArpoBrpoCrpoZrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 known ✓ | O43570 | 3/20 | 0.49 |
| ▸ | CA1 known ✓ | P00915 | 3/20 | 0.49 |
| ▸ | CA2 known ✓ | P00918 | 3/20 | 0.49 |
| ▸ | MEN1 | O00255 | 3/20 | 0.63 |
| ▸ | POLB | P06746 | 3/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.63 |
| ▸ | PKM | P14618 | 1/20 | 0.63 |
| ▸ | TDP1 | Q9NUW8 | 5/20 | 0.58 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.58 |
| ▸ | MAPT | P10636 | 1/20 | 0.58 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.58 |
| ▸ | TSHR | P16473 | 2/20 | 0.55 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | CA9 | Q16790 | 4/20 | 0.49 |
| ▸ | NSD2 | O96028 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | PLCG1 | P19174 | 1/20 | 0.49 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30932792 | 0.85 | KMT2A (0.67) | MEN1POLBKMT2AALDH1A1PKM | |
| SCHEMBL1564742 | 0.85 | KMT2A (0.67) | MEN1POLBKMT2AALDH1A1PKM | |
| SCHEMBL1459627 | 0.84 | CASP6 (0.65) | MEN1POLBKMT2AALDH1A1PKM | |
| SCHEMBL1911571 | 0.83 | CA2 (0.68) | MEN1POLBKMT2AALDH1A1PKM | |
| SCHEMBL1131324 | 0.81 | CASP6 (0.67) | MEN1POLBKMT2AALDH1A1PKM | |
| SCHEMBL913390 | 0.81 | ALDH1A1 (0.68) | MEN1POLBKMT2AALDH1A1PKM | |
| SCHEMBL4865932 | 0.81 | MEN1 (0.63) | MEN1POLBKMT2AALDH1A1PKM | |
| SCHEMBL7772187 | 0.81 | MEN1 (0.68) | MEN1POLBKMT2AALDH1A1PKM | |
| SCHEMBL11201358 | 0.81 | VCAM1 (0.47) | MEN1POLBKMT2AALDH1A1PKM | |
| SCHEMBL1366872 | 0.80 | CASP6 (0.65) | MEN1POLBKMT2AALDH1A1PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 91 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105949590-A | Tensile cable sheath material and preparation method thereof | 安徽华星电缆集团有限公司 | 2016-09-21 | — | — | CN | claimed |
| US-20260145165-A1 | BACKSIDE POLISHING ADDITIVE FOR REDUCING ALKALI CONSUMPTION AND PREPARATION METHOD AND USE THEREOF | Han, Gengxin (US) | 2026-05-28 | — | — | US | disclosed |
| CN-119932712-A | Texturing additive for improving efficiency of solar cell and preparation method and application thereof | 韩庚欣 | 2025-05-06 | — | — | CN | disclosed |
| CN-119505712-A | Back polishing additive for reducing alkali consumption and preparation method and application thereof | 韩庚欣 | 2025-02-25 | — | — | CN | disclosed |
| US-20240167922-A1 | TRANSPARENTIZING REAGENT AND TRANSPARENTIZING METHOD | KYOTO UNIVERSITY (JP) | 2024-05-23 | — | — | US | disclosed |
| EP-4306927-A1 | TRANSPARENTIZING REAGENT AND TRANSPARENTIZING METHOD | Kyoto University (JP) | 2024-01-17 | — | — | EP | disclosed |
| WO-2022191336-A1 | TRANSPARENTIZING REAGENT AND TRANSPARENTIZING METHOD | 国立大学法人京都大学 | 2022-09-15 | — | — | WO | disclosed |
| CN-111295466-A | Electroless nickel-phosphorus-cobalt plating bath and electroless nickel-phosphorus-cobalt plating film | 上村工业株式会社 | 2020-06-16 | — | — | CN | disclosed |
| CN-105949590-A | Tensile cable sheath material and preparation method thereof | 安徽华星电缆集团有限公司 | 2016-09-21 | — | — | CN | disclosed |
| CN-105949590-A | Tensile cable sheath material and preparation method thereof | 安徽华星电缆集团有限公司 | 2016-09-21 | — | — | CN | disclosed |
| EP-1579277-A1 | POLYHYDROXYALKANOATE CONTAINING AMIDE GROUP, SULFONIC GROUP, AND SULFONATE ESTER GROUP, METHOD FOR PRODUCING THE SAME, AND CHARGE CONTROL AGENT, TONER, IMAGE FORMING METHOD, AND IMAGE FORMING APPARATUS | Canon Kabushiki Kaisha (JP) | 2005-09-28 | — | — | EP | disclosed |
| EP-1579276-A1 | NOVEL POLYHYDROXYALKANOATE HAVING AMIDE, SULFONIC ACID OR SULFONATE ESTER GROUP, CHARGE CONTROL AGENT AND TONER | CANON KABUSHIKI KAISHA (JP) | 2005-09-28 | — | — | EP | disclosed |
| EP-1086076-B1 | SULFONAMIDE INHIBITORS OF ASPARTYL PROTEASE | VERTEX PHARMA (US) | 2004-12-22 | — | — | EP | disclosed |
| WO-2004061529-A1 | NOVEL POLYHYDROXYALKANOATE HAVING AMIDE, SULFONIC ACID OR SULFONATE ESTER GROUP, CHARGE CONTROL AGENT AND TONER | CANON KABUSHIKI KAISHA (JP) | 2004-07-22 | — | — | WO | disclosed |
| WO-2004061530-A1 | POLYHYDROXYALKANOATE CONTAINING AMIDE GROUP, SULFONIC GROUP, AND SULFONATE ESTER GROUP, METHOD FOR PRODUCING THE SAME, AND CHARGE CONTROL AGENT, TONER, IMAGE FORMING METHOD, AND IMAGE FORMING APPARATUS | CANON KABUSHIKI KAISHA (JP) | 2004-07-22 | — | — | WO | disclosed |
| US-20040097594-A1 | Sulfonamide inhibitors of aspartyl protease | HALE MICHAEL ROBIN (US) | 2004-05-20 | — | — | US | disclosed |
| US-6613743-B2 | Administering to a patient suffering from viral infections a sulfonamides antiviral agents which are aspartyl protease inhibitors | VERTEX PHARMACEUTICALS INCORPORATED | 2003-09-02 | — | — | US | disclosed |
| EP-1235825-A1 | NOVEL BENZOIMIDAZOLE DERIVATIVES USEFUL AS ANTIPROLIFERATIVE AGENTS | Pfizer Products Inc. (US) | 2002-09-04 | — | — | EP | disclosed |
| US-20020049201-A1 | Sulfonamide inhibitors of aspartyl protease | VERTEX PHARMACEUTICALS INCORPORATED | 2002-04-25 | — | — | US | disclosed |
| WO-2001040217-A1 | NOVEL BENZOIMIDAZOLE DERIVATIVES USEFUL AS ANTIPROLIFERATIVE AGENTS | PFIZER PRODUCTS INC. (US) | 2001-06-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040097594-A1 | Sulfonamide inhibitors of aspartyl protease | SPINT2, PRSS1, DNPEP | CA12 397/4885CA1 394/4885CA2 409/4885 |
| US-20020049201-A1 | Sulfonamide inhibitors of aspartyl protease | SPINT2, PRSS1, DNPEP | CA12 397/4885CA1 394/4885CA2 409/4885 |
| US-20240167922-A1 | TRANSPARENTIZING REAGENT AND TRANSPARENTIZING METHOD | TST, TTR, ALB | CA12 79/4885CA1 377/4885CA2 2629/4885 |
| US-20260145165-A1 | BACKSIDE POLISHING ADDITIVE FOR REDUCING ALKALI CONSUMPTION AND PREPARATION METHOD AND USE THEREOF | DBH, LMNA, BCOR | CA12 484/4885CA1 182/4885CA2 188/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.